Conference Presentation, Panel
Global Health: Connectiveness for Better Outcomes | Asia Summit 2024
- The Snow Research Foundation aims to facilitate long-term community change through eight-year fellowships, funding approximately 100 bold young researchers across regions including Indonesia, India, and Singapore to deliver technologies 20 to 40 years ahead of the academic system.
- Future funding rounds for the Snow Fellowship will transition from grants to equity to foster entrepreneurship, with a specific target to increase the proportion of women applicants and address a historical 90% male dominance, while deepening partnerships in Singapore, Hong Kong, mainland China, and Japan.
- The Snow Foundation anticipates immediate benefits within one to two years regarding enhanced EMR systems in Australia to accelerate trials, while immunology research is expected to potentially cure various diseases, though the success of current early-stage work remains uncertain.
- The Snow Fellowship program is designed as a long-term partnership extending beyond the 10-year mark contingent on collaboration success, with the expectation that roughly half of its future output will stem from backing top-tier young talent.
- Mubadala plans to increase its Asia asset allocation from approximately 12 percent to 25 percent over the next 2.5 years, aiming to deploy large-scale capital tickets ranging from $500 million to $1 billion despite fewer opportunities compared to the West.
- Mubadala intends to deepen regional partnerships in East Asia, scale Manipur hospitals across India with TPG partners, support Austin's dental implants business globally with MBK and Unison Capital, and carve out mature pharma portfolios from multinational companies to serve domestic Chinese markets.
- Leveraging over $300 billion in assets, Mubadala expects to utilize AI and technology to address rising healthcare demand and will focus heavily on women's health to correct historical exclusions from clinical trials prior to the 1990s.
- TPG Capital will maintain healthcare as its primary sector focus and expects to expand its clinical trial CRO operations, which have generated 60 drugs from over 6,000 trials with less than 30 percent currently in Australia.
- Driven by projections that 60 percent of the global population over 65 will reside in Asia by 2030 and that the region will account for 20 percent of the global healthcare budget, TPG Capital aims to migrate its Southeast Asia strategy toward value-for-health initiatives and expand over-the-counter medication access.
- TPG Capital plans to experiment with home care post-treatment in India to address doctor shortages, continue investing in medical training for health professionals, and expects several portfolio companies held for over five years to scale into $1 billion businesses.
- Mubadala aims to address the anticipated trend of Japan's aging population, where 30 percent are expected to be aged 65 and up, to drive demand for long-term care, elderly care, and remote monitoring technologies.